Oritavancin News
Most Popular Oritavancin Story
FDA backs Theravance antibiotic, rejects Targanta's
Theravance won the crucial backing of an FDA advisory committee for its new antibiotic for serious skin infections. The panel voted 21 to 5 to recommend approval of telavancin, which is also designed... Read more...
Latest Headlines
- January 13, 2009
- December 19, 2008
- December 9, 2008
- November 20, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
